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Karela is a common name of Momordica charantia. The present study 
was carried out to study the herb drug interactions between the 
traditional medicine Karela with Thiazolindinediones, Pioglitazone in 
normal and diabetic conditions. Blood samples were collected from rats 
by retro orbital puncture at regular intervals of time 0, 1, 2, 3, 4, 6, 8, 
10, 12 hr of rats treated with Pioglitazone 5, 10 and 20mg/kg bd.wt and 
Momordica charantia 100 and 200mg/kg bd.wt. The Pioglitazone and 
Karela showed dose dependent reduction of blood glucose levels. The 
optimum blood glucose reduction was obtained at 10mg/kg of 
pioglitazone and 200mg/kg of Karela in normal rats. The blood glucose 
levels were found to be decreased with corresponding elevated insulin 
levels in both single and multiple dose combinations of Pioglitazone 
and Karela in normal rats (4hr) as well as in alloxan induced diabetic 
rats (4hr) compared with the pioglitazone alone. Since the combination 
of Karela and pioglitazone produced severe hypoglycemia in combined 
treatment due to pharmacodynamic interactions, care must be taken 
while prescribing the combination in clinical situation. 
 
                 Copy Right, IJAR, 2019,. All rights reserved. 
…………………………………………………………………………………………………….... 
Introduction:- 
Herbal medicines are popular used preventive remedies for many diseases and play a key role in the human health 
care of a vast majority of world’s population.   From last five thousand years human being has relied on natural 
product as the primary source of medicines. However, the last two centuries have brought an explosion to 
understand how the natural products are produced and how they react with other organisms. The World Health 
Organization (WHO) estimates that 80% of the world health populations presently use herbal medicines for some 
aspect of primary health care [1]. Millions of people now a day’s use herbal medicines along with prescription and 
non-prescription medications that the natural agents are safer than the conventional synthetic chemo therapeutic 
agents [2]. 
 
The herbs are alternative treatment option apart from the convention drug therapy is now day practice in patients 
with diabetes and other associated complications. Polypharmacy is a common phenomenon in the type 2 diabetes. 
The most commonly used alternatives are herbs and herbal formulations. But they initiate many herb drug 
interactions without any previous reports. Even the monographs of existed drugs had data regarding the drug-drug 
interactions but not about herb-drug interactions [3]. The drug interaction may be either pharmacokinetic or 
pharmacodynamic interactions at the one dose or at another dose of toxic lead to either agonistic or antagonistic 
Corresponding Author:-Rajasekhara Reddy T. 
Address:-Clinwave Research Private Limited, Kukatpally, Hyderabad. 
 
ISSN: 2320-5407                                                                                  Int. J. Adv. Res. 7(4), 1254-1258 
1255 
 
reactions tends to in effectiveness of intended drug or enhanced pharmacological actions. Research need to explore 
the unexplored drug interactions of combined use of herb drugs for therapeutic outcomes.  Based on the research 
outcomes, it needs to adjust the dosage regimen and individualization.  
 
Diabetes is a metabolic disease, where there is a chance of concomitant administration of many herbs with oral 
hypoglycemic agents. There is a possibility of herb-drug interactions in terms of pharmacokinetic and 
pharmacodynamic interactions which affecting safety and efficacy of the prescribed medicines in diabetic condition. 
Antidiabetic drugs have been found to potential interactions with co-administered herbs due to CYP enzymes. Some 
of the examples are pioglitazone, repaglinide, and rosiglitazone acts substrates for CYP2C8; glibenclamide, 
glimepiride, glipizide, nateglinide, and rosiglitazone for CYP2C9; pioglitazone and repaglinide for CYP3A4 [4]. 
Pioglitazone is metabolized by CYP 2C8 and CYP3A4 microsomal liver enzymes [5]. Herbal medicines that 
modulate intestinal and hepatic CYPs can alter the bioavailability and clearance of co-administered drugs. Example 
Moringa oleifera with simultaneous administration of Pioglitazone potentiate the activity of pioglitazone by 
decreasing the metabolism of pioglitazone as a result of inhibition CYP3A4 [6]. Momordica charantia, commonly 
called as Karela used as herbal remedy for diabetes. People are used as home remedy as well as available in herbal 
drug and in many herbal formulation marketed by popular companies such as Himalaya, Patangali, Herbal Hills, 
Healing herbs, Panchaveda,  Morpheme, Dr. Wakede’s, Sri Sri, Vedic etc.  Hence, there is chance of co 
administration of widely prescribe Pioglitazone with Karela. The present study was planned to conduct the 
pharmacodynamic interactions between the Pioglitazone and Momordica charantia in normal and diabetic rats. 
 
Materials and Methods:- 
Animals: 
Albino rats of either sex obtained from M/s. Mahaveer Enterprises, All animals were maintained on pellet diet 
supplied by M/s. Rayan Biotechnologies Pvt. Ltd., Hyderabad with 12h/12h light/dark cycle and water ad libitum. 
Animals were fasted for 18 h before the experiment. The Momordica charantia obtained from Laila impex Pvt Ltd., 
Vijayawada as gift sample. 
 
Study in normal rats  
A group of six albino rats weighing between 250-300 g were administered with 5, 10 and 20mg/ kg body weight 
Pioglitazone, orally. The same group was administered with 100 and 200mg/kg body weight Momordica charantia, 
orally after a wash out period of one week. The same group was also administered with 200 mg/ kg body weight 
Momordica charantia 30 min prior to 10mg/ kg body weight Pioglitazone, after a further wash out period of 1 week. 
Blood samples were withdrawn from retro orbital puncture at 0, 1, 2, 4, 6, 8, 10, and 12h intervals. Blood samples 
were analyzed for blood glucose levels by GOD/POD method [7] using commercial glucose kits (Span diagnostics) 
insulin levels were estimated by using ELISA kits. 
 
Study in diabetic rats  
Diabetes was induced by the administration of alloxan monohydrate in two doses 100 mg and 50mg/ kg body weight 
intraperitoneal for two consecutive days [8]. A group of 6 rats with blood glucose levels above 250 mg/dL was 
selected for the study. The study similar to the one conducted in normal rats was repeated in diabetic group. 
Data and Statistical Analysis: Data was expressed as mean ± standard error of mean (SEM). The significance was 
determined by Two way ANOVA, Bonferroni post test. 
 
Results &Discussion:- 
Induction of CYP enzyme can lower the plasma concentration of concurrently administered drugs and leads to 
reduced therapeutic benefit. To assess the interaction between the Pioglitazone and Karela (Momordica charantia), 
the study was designed to indentify the pharmacodynamic interactions in both normal and in alloxan induced 
diabetic rats.  Pioglitazone at 5, 10 and 20mg/kg bd.et and aqueous fruit extracts of Momordica charantia (AQMC) 
at 100, 200 and 300 mg/kg bd.wt were selected in this study to identify the dose dependent blood glucose reduction.  
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Figure 1:-Comparison of % blood glucose reduction of Pioglitazone 5mg/kg, 10mg/kg and 20mg/kg. 
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Figure 2:-Comparison of % blood glucose reduction of AEMC (100mg/kg, 200mg/kg and 300mg/kg). 
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Figure 3:-Comparison of % blood glucose reduction of Pioglitazone 10mg/kg, AEMC (200mg/kg) and single and 
multiple dose Combinations in normal rats 
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Table 1:-Mean Serum insulin (µIU/mL) with mean serum glucose level (mg/dL) in Pioglitazone, AEMC and single 
and multiple dose treatment AEMC +Pioglitazone: 
Groups  
Time (hrs) 
Mean  serum glucose 
levels (mg/dL) 
Serum Insulin (μIU/mL) 
Pioglitazone 0hr 82.17±1.64 9.47±0.11 
2hr 60.33±1.29 11.39±0.09 
AEMC 3hr 57.83±1.53 12.13±0.05 
AEMC + Pioglitazone (SD) 4hr 56.17±1.25 12.17±0.05 
AEMC + Pioglitazone (MD) 4hr 52.17±1.31 13.30±0.04 
 
Figure 4:-Comparison of % blood glucose reduction of Pioglitazone 10mg/kg, AEMC (200mg/kg) and single and 
multiple dose Combinations in Diabetic rats 
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Table 2:-Mean Serum insulin (µIU/mL) with mean serum glucose level (mg/dL) in Pioglitazone, AEMC and single 
and multiple dose treatment AEMC +Pioglitazone 
Groups  
Time (hrs) 
Mean  serum glucose 
levels (mg/dL) 
Serum Insulin (μIU/mL) 
Pioglitazone 0hr 262.33 6.59 6.33±0.03 
2hr 167.67 4.61 7.25±0.01 
AEMC 3hr 186.83 2.96 7.07±0.03 
AEMC + Pioglitazone (SD) 4hr 148.33 4.57 7.72±0.02 
AEMC + Pioglitazone (MD) 4hr 143.00 5.47 7.79±0.02 
 
In normal rats, Pioglitazone and AEMC when administered alone produced significant decrease in blood glucose 
level in a dose dependent manner. A dose of 10 mg/kg of Pioglitazone and 200 mg/kg of AQMC bd.wt found to 
have optimal reduction in blood glucose levels (about 30%) as shown in graph 1 and 2. The insulin levels were 
found to be enhanced at peak reduction of blood glucose with AEMC at 3hr compared to 0hr (table 1). In 
combination, the selected dose of AEMC found to enhance the hypoglycemic activity produced by Pioglitazone with 
single dose and as well as multiple dose treatments also. The insulin levels at peak reduction in blood glucose levels 
were also found to be altered with single and multiple dose treatments (graph 3). This indicates there is an existence 
of pharmacodynamic interaction between AEMC and Pioglitazone in normal rats. A dose of 200mg/kg bd.wt found 
to have 32% reduction in blood glucose levels.  The insulin levels were found to be enhanced slightly at peak 
reduction of blood glucose with AEMC at 3hr compared to 0hr. The alloxan used to induce diabetes in the present 
study.  
 
Alloxane is commonly used diabetes inducing agent. It works by inducing the sudden release of insulin from 
pancreatic β cells. The islet response to glucose even when high concentrations of glucose were used [9]. Further, 
the alloxan action in the pancreas is preceded by its rapid uptake by pancreatic beta cells that have been proposed to 
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be one of the important features determining alloxan diabetogenicity. In combination, the selected dose of AEMC 
found to enhance the antihyperglycemic activity produced by Pioglitazone with single dose and multiple dose 
treatments in diabetic rats (graph 4). The insulin levels at peak reduction in blood glucose levels were also found to 
be altered with single and multiple dose treatments. This indicates there is an existence of pharmacodynamic 
interaction between AEMC and Pioglitazone in diabetic rats. The Pharmacodynamic interaction may be due to their 
synergistic antihyperglycemic effect or due to inhibition of metabolism of Pioglitazone as Momordica charantia 
reported to have inhibitory activity on CYP 3A4 and CYP 2C19 [10]. 
 
The same results were also found in the studies conducted Simone B., 2012 [11]., Momordica charantia reported to 
have inhibitory activity against the CYP 1A1, CYP2C19 and CYP3A4 I in invitro. Lal VK., 2011 reported that 
Momordica charantia shows synergistic effect with glibenclamide [12] and metformin [13] by elevating the blood 
glucose levels. Nivitabishekam SN., 2009 also reported that the Momordica charantia potentiates the hypoglycemic 
effect of Rosiglitazone in both normal and STZ induced diabetes [14]. The same might be responsible for synergistic 
hypoglycemic and antihyperglycemic activity of Pioglitazone with Karela.  
 
Conclusions:- 
The combinations are not safe in rats; care must be taken when they are administered with pioglitazone to avoid 
severe hypoglycemia. The herbal drug manufacturers also need to provide the information regarding the potent and 
possible herb drug interactions of used herbs. 
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